Sponsor: Mersana Therapeutics
Sponsor Study ID: MER-XMT-1536-3
Study Title: A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Upifitamab Rilsodotin (XMT 1536) as Post Platinum Maintenance Therapy for Participants with Recurrent, Platinum Sensitive Ovarian Cancer (UP NEXT)
CTO #: 103536
NCT Number: NCT05329545
Phase: III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Ovary
Study Objectives: